U.S. flag An official website of the United States government
  1. Home
  2. Science & Research
  3. FDA Technology Transfer Program
  4. Licensing and Collaboration Opportunities
  5. Multivalent Meningiococcal Conjugates and Methods for Preparing Conjugates
  1. Licensing and Collaboration Opportunities

Multivalent Meningiococcal Conjugates and Methods for Preparing Conjugates

Download the Abstract (PDF - 88KB)

Technology Summary

Among 13 isolated meningococcal serogroups, A, B, C, W-135 and Y are the most prevalent. There are three FDA-approved capsular polysaccharide (PS)-based vaccines, one tetravalent PS vaccine, and two tetravalent conjugate vaccines for protection against meningococcal disease caused by groups A, C, W-135 and Y Neisseria meningitidis. However, there is no (PS)-based vaccine for Group B capsular PS. There is a genuine need to develop novel meningococcal vaccines, particularly for group B and group X meningococcal serogroups.

FDA inventors developed a modified CDAP (1-cyano-4-dimethylaminopyridinium tetrafluoroborate) conjugation method where meningococcal factor H binding protein (fHbp) conjugates with groups A, C, W-135 and PS. The resulting conjugates serve as effective carriers for PS in mice. The induced antisera are bactericidal against both serogroups A, C, W-135 and Y AND serogroup B. Further, the antisera are bactericidal for serogroup X strains that that express fHbp1 on its surface.

Potential Commercial Applications Competitive Advantages
  • Multivalent meningitis vaccine
  • Research tool
  • Higher vaccine yield
  • More efficient conjugation method
  • Lower cost vaccines

Inventors: Che-Hung Robert Lee, Vavlerian Pinto

Publications:
Pinto VB, Burden R, Wagner A, Moran EE, Lee CH. The development of an experimental multiple serogroups vaccine for Neisseria meningitidis. PLoS One. 2013;8(11):e79304. Published 2013 Nov 14. doi:10.1371/journal.pone.0079304

Intellectual Property: United States Patent No. US 9,427,476 issued 08.30.2016

Product Area:  Vaccine, multivalent vaccine, CDAP conjugation

FDA Reference No: E-2012-005

Licensing Contact:
Ken Millburne, J.D.
FDA Technology Transfer Program
Email: FDAInventionlicensing@fda.hhs.gov 
Phone: 301-346-3964

Back to Top